文献速递乳腺癌

乳腺癌中雄激素受体功能与雄激素受体靶向治疗:综述

Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
PubMed 文献 · JAMA Oncol · 2017-01-01

本综述通过分析临床前研究、回顾性临床研究和临床试验,探讨了乳腺癌中雄激素受体(AR)及其相关通路的生物学、AR靶向治疗的潜力以及潜在生物标志物。AR在乳腺癌中的阳性率约为60%至80%,AR靶向治疗(包括AR激动剂、AR拮抗剂和PI3K抑制剂)在临床试验中显示出有希望的结果,但用于分层患者的生物标志物尚未确立。

要点

  • 乳腺癌中AR阳性率约为60%至80%。
  • AR通路与PI3K/Akt/mTOR、MAPK通路以及雌激素受体和人表皮生长因子受体-2存在交叉对话。
  • AR靶向治疗在乳腺癌临床试验中显示出有希望的结果,但生物标志物尚未确立。

核心结论

  • 乳腺癌的AR靶向治疗尚在开发中,已显示出有希望的初步结果;深入了解AR及相关信号通路将改善AR阳性乳腺癌的治疗策略;有必要进行进一步的临床前和临床研究以阐明AR生物学并指导AR靶向治疗的发展。

研究设计与样本

  • 综述,通过回顾临床前研究、回顾性临床研究和临床试验,检查AR及相关通路的生物学、AR靶向治疗在乳腺癌中的潜力和潜在生物标志物。

主要发现

  • 乳腺癌中AR阳性率约为60%至80%。
  • AR通路与PI3K/Akt/mTOR和MAPK通路以及雌激素受体和人表皮生长因子受体-2存在交叉对话。
  • AR阳性作为预后标志物的价值尚未确定。
  • AR靶向治疗(包括AR激动剂、AR拮抗剂和PI3K抑制剂)在乳腺癌患者的临床试验中显示出有希望的结果,AR靶向治疗与其他药物的联合已被研究用于克服AR靶向治疗的耐药性。
  • 用于根据对AR靶向药物反应可能性分层患者的生物标志物尚未建立;AR抑制剂反应的潜在生物标志物包括AR磷酸化和AR基因表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • AR阳性作为预后标志物的价值尚未确定。
  • 用于根据对AR靶向药物反应可能性分层患者的生物标志物尚未建立。
  • 有必要进行进一步的临床前和临床研究以阐明AR生物学并指导AR靶向治疗的发展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. To date, AR-targeted drugs have been approved only for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation. Through review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-related pathways, the potential for AR-targeted therapies in breast cancer, and potential biomarkers for AR-targeted treatments. OBSERVATIONS: The rate of AR positivity in breast cancer is about 60% to 80%. Biologically, the AR pathway has cross-talk with several other key signaling pathways, including the PI3K/Akt/mTOR and MAPK pathways, and with other receptors, including estrogen receptor and human epidermal growth factor receptor-2. The value of AR positivity as a prognostic marker has not yet been defined. Androgen receptor-targeted therapies, including AR agonists, AR antagonists, and PI3K inhibitors, have shown promising results in clinical trials in patients with breast cancer, and combinations of AR-targeted therapies with other agents have been investigated for overcoming resistance to AR-targeted therapies. Biomarkers to stratify patients according to the likelihood of response to AR-targeted drugs are yet to be established. Potential biomarkers of response to AR inhibitors include AR phosphorylation and AR gene expression. CONCLUSIONS AND RELEVANCE: Androgen receptor-targeted treatments for breast cancer are in development and have shown promising preliminary results. In-depth understanding of AR and AR-related signaling pathways would improve the treatment strategies for AR-positive breast cancer. Further preclinical and clinical studies of AR-targeted drugs alone and in combination with other drugs are justified and warranted to clarify the biology of AR and inform the development of AR-targeted therapies to improve survival outcome in patients with breast cancer.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kono M, Fujii T, Lim B, et al. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017. PMID: 28301631. doi:10.1001/jamaoncol.2016.4975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。